A randomized clinical trial to determine efficacy of Ayurveda medicine in the treatment COVID 19 patients

To determine the therapeutic efficacy of NF2 and NF4 in the treatment of COVID-19

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2021/08/036025

Enrollment

100

Registered

2021-08-31

Start date

Unknown

Completion date

Unknown

Last updated

2022-10-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: B972- Coronavirus as the cause of diseases classified elsewhere

Interventions

None listed

Eligibility

Inclusion criteria

Inclusion criteria: FEVER >98.6 DEGREE F SYMPTOMATIC COVID 19 INFECTION WITHOUT CO MORBIDITY WILLINGNESS TO PARTICIPATE IN THE STUDY SpO2 >93% nationality Indian

Exclusion criteria

Exclusion criteria: AGE 70 T2DM CKD BA CVA CVS DISORDER COPD PREGNANCY AND LACTATION MALIGNANCY

Design outcomes

Primary

Measure	Time frame
Primary TO CONTROL THE SIGN AND SYMPTOM OF COVID19 RTPCR NEGATIVE Timepoint: day 1 day 5 day 10	—

Secondary

Measure	Time frame
Secondary Trial drug will be more effective than placebo change in biomarkersTimepoint: day 1 day 5 day 10	—

Countries

India

Contacts

Public ContactDr Sanjib kumar Das

Sri Sri College of Ayurvedic Science and Research Hospital

sanjib.d@srisriuniversity.edu.in9437292457

Outcome results